A cancer treatment comprises the administration of a pro-drug compound identified by an in silico candidate identification screening. The pro-drug candidates are selected from a data base and calculations are carried out on the association of the pro-drug candidates to form a complex with a metal ion and a proteasome active site. The pro-drug inhibits the active site of the proteasome in the presence of the metal ion and has little or no effect in the absence of the metal ion. The pro-drug can be: 3,4-dihydroxybenzoic acid; galloflavin; 2-[(carbamoylsulfanyl)acetyl]amino}benzoic acid; 6,7-Dihydroxycoumaranone; 3,6-bis(hydroxymethyl)pyridazin-4(1H)-one; and 4′,5,7-trihydroxyisoflavone, for binding with copper ion and proteasome.
Heilmittelchemische Studien in der heterocyclischen Reihe. 23. Mitteilung. Pyridazine XI. Die Reaktion von Kojisäure mit Hydrazin. 1. Teil
作者:A. F. Thomas、A. Marxer
DOI:10.1002/hlca.19580410645
日期:——
It has been shown that the reaction between kojic acid and hydrazine hydrate gives rise to two main products: 3,6-dihydroxymethyl-4-oxo-1,4-dihydro-pyridazine, and the hydrazone of 3-hydroxymethyl-pyrazol-5-yl-hydroxyacetaldehyde, the structures of which were proved unambiguously.